Skip to main content

Advertisement

SpringerLink
Log in

Cost-Effectiveness of Eplerenone in Patients with Left Ventricular Dysfunction after Myocardial Infarction—An Analysis of the EPHESUS Study from a Swiss Perspective

  • Pharmaco-Economics
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Objective

The EPHESUS study demonstrated that aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction (LVSD) and heart failure after acute myocardial infarction (AMI). The EPHESUS pharmacoeconomic analysis was performed to evaluate the cost-effectiveness of eplerenone in the Swiss setting.

Materials and methods

A total of 6,632 patients with LVSD and heart failure after AMI were randomized to eplerenone or placebo and followed for a mean of 16 months. The co-primary endpoints were all-cause death and the composite of cardiovascular death/cardiovascular hospitalization. The evaluation of resource use included hospitalizations, outpatient services, and medications. Survival beyond the trial period was estimated using data from the Framingham Heart Study, the Saskatchewan Health database, and the Worcester Heart Attack Registry. The incremental cost-effectiveness of eplerenone in cost per life-year and quality-adjusted life-year gained was estimated. The perspective of the Swiss third party payers was used. Daily treatment costs of eplerenone were set at CHF 3.88. All other resources were valued on the basis of official tariffs. Discounting of the results was performed at a rate of 3%.

Results

The number of life-years gained with eplerenone was 0.1083 based on Framingham, 0.0661 with Saskatchewan and 0.1518 with Worcester survival estimates. Total costs were CHF 1,028 higher over the trial period in the eplerenone arm, due to drug cost. The incremental cost-effectiveness ratio was CHF 10,145 per life-year gained with Framingham, CHF 16,178 with Saskatchewan, and CHF 7,693 with Worcester survival estimates. The corresponding costs per QALY were CHF 15,219, CHF 23,965 and CHF 11,337, respectively.

Conclusion

Eplerenone is effective in reducing mortality and, in Switzerland, is also cost-effective in increasing years of life for patients with LVSD after AMI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dargie HJ, McMurray JJ, McDonagh TA. Heart failure—implications of the true size of the problem. J Intern Med 1996;239(4):309–15.

    Article  PubMed  CAS  Google Scholar 

  2. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 1999;20(6):447–55.

    Article  PubMed  CAS  Google Scholar 

  3. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24(5):442–63.

    Article  PubMed  CAS  Google Scholar 

  4. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail 1999;1(3):229–41.

    Article  PubMed  CAS  Google Scholar 

  5. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE. The epidemiology of heart failure. Eur Heart J 1997;18:208–25.

    PubMed  CAS  Google Scholar 

  6. Szucs T. [Health economic aspects of chronic heart failure. Part 1: Burden of disease and economic appraisal.] Gesundheitsökonomische Aspekte der chronischen Herzinsuffizienz. Teil 1: Krankheitslast und ökonomische Bewertung. Schweizerische Ärztezeitung 2003;84(46):2431–5 (www.saez.ch; last accessed July 5, 2005)

  7. Szucs TD. The growing healthcare burden of CHF. J Renin Angiotensin Aldosterone Syst 2000 Sep;1(Suppl 1):2–6

    PubMed  Google Scholar 

  8. Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005;111(9):1106–13.

    Article  PubMed  Google Scholar 

  9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14): 1309–21.

    Article  PubMed  CAS  Google Scholar 

  10. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone post-AMI heart failure efficacy and survival study. Cardiovasc Drugs Ther 2001;15(1):79–87.

    Article  PubMed  CAS  Google Scholar 

  11. Schulman K, Burke J, Drummond M, Davies L, Carlsson P, Gruger J, Harris A, Lucioni C, Gisbert R, Llana T, Tom E, Bloom B, Willke R, Glick H. Resource costing for multinational neurologic clinical trials: methods and results. Health Econ 1998;7(7):629–38.

    Article  PubMed  CAS  Google Scholar 

  12. Casemix E. Main results of the Swiss study on DRGs (Casemix Study). Soz Praventivmed 1989;34(4):156–66.

    Article  PubMed  CAS  Google Scholar 

  13. www.tarmed.ch (last accessed April 2005)

  14. Arzneimittelkompendium der Schweiz (Swiss Formulary), Documed, Basel, 2005.

  15. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS; TACTICS-TIMI 18 Investigators. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002;288:1851–8.

    Article  PubMed  Google Scholar 

  16. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002;23:458–66.

    Article  PubMed  CAS  Google Scholar 

  17. Franco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: Life course analysis. Hypertension 2005;46:280–286.

    CAS  Google Scholar 

  18. Downey W, Beck P, McNutt M, Stang MR, Osei W, Nichol J. Health databases in Saskatchewan. In: Strom BL, editor. Pharmacoepidemiology, 3rd ed. Chichester: Wiley; 2000. p. 325–45.

    Google Scholar 

  19. Goldberg RJ, Yarzebski J, Lessard D, Gore JM. A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 1999;33:1533–39.

    Article  PubMed  CAS  Google Scholar 

  20. Spencer FA, Meyer TE, Goldberg RJ, Yarzebski J, Hatton M, Lessard D, Gore JM. Twenty year trends (1975–1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 1999;34:1378–87.

    Article  PubMed  CAS  Google Scholar 

  21. Blackstone EH, Naftel DC, Turner MEJ. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. J Am Stat Assoc 1986;81:615–24.

    Article  Google Scholar 

  22. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS, for the TACTICS-TIMI 18 Investigators. Treat Angina with Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction: cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002;288:1851–58.

    Article  PubMed  Google Scholar 

  23. Rabin R, De Charro F. EQ-5D: a measure of health status from the EuroQoL group. Ann Med 2001;33:337–43.

    PubMed  CAS  Google Scholar 

  24. Erne P, Radovanovic D, Urban P, Stauffer J-C,Bertel O, Gutzwiller F. Early drug therapy and in-hospital mortality following acute myocardial infarction. Heart Drug 2003;3:134–40.

    Article  CAS  Google Scholar 

  25. Ess SM, Szucs TD. High dose lisinopril in heart failure: economic considerations. Cardiovasc Drugs Ther 2002;16:365–71.

    Article  PubMed  CAS  Google Scholar 

  26. Szucs T, Berger K, Schulte-Hillen J, Kleber FX. Die Wirtschaftlichkeit von Captopril nach Myokardinfarkt. Med Klinik 1996;91:112–18.

    CAS  Google Scholar 

  27. Szucs TD, Meier B. Kosten-Effektivität von Atorvastatin bei Patienten mit akutem Koronarsyndrom. Eine Analyse der der PROVE-IT Studie. Kardiovaskuläre Medizin 2004;7:412–20.

    Google Scholar 

  28. Goldmann L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adreneric antagonists after acute myocardial infarction. N Engl J Med 1988;319:152–57.

    Article  Google Scholar 

  29. Szucs TD, Bertel O, Darioli R, Gutzwiller F, Mordasini R. Ökonomische Evaluation von Pravastatin in der Behandlung der koronaren Sekundärprävention. Eine Analyse auf der Basis der LIPID Studie (Economical and pharmacological valuation of pravastatin in secondary coronary prevention) Schw Rundschau Med Praxis 2000;57:1667–73.

  30. Taylor WC, Pass TM, Shephard DS, Komaroff AL. Cost-effectiveness of cholesterol reduction for the primary prevention of coronary heart disease in men. Preventing disease: Beyond the rhetoric. New York: Springer; 1990.

    Google Scholar 

  31. Cathomas G, Erne P, Schwenkglenks M, Szucs T. The economic efficiency of Amlodipine on the treatment of coronary Atherosclerosis—an analysis based on the PREVENT study. Cardiovasc Drugs Ther 2002;16:61–6.

    Article  PubMed  CAS  Google Scholar 

  32. Szucs TD, Darioli R. Kosten-Effektivität von Perindopril bei Patienten mit koronarer Herzkrankheit in der Schweiz—Eine Analyse der Europa Studie. Kardiovaskuläre Medizin 2004;7:443–52.

    Google Scholar 

  33. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977;296:732–9.

    Article  PubMed  CAS  Google Scholar 

  34. Szucs TD, Müller D, Darioli R. Schweizer Analyse der ASCOT-Studie: Wie kosten-effektiv sind Statinen in der coronaren Prävention? Cardiovasc 2003;5:29–32.

    Google Scholar 

  35. Haldemann R, Lüscher TF, Szucs TD. Die Wirtschaftlichkeit von Clopidogrel in der kardiovaskulären Sekundärprävention: eine Kosten-Effektivitäts-Analyse auf der Grundlage der CAPRIE-Studie. [Cost Effectiveness of Clopidogrel in the Secondary Prevention of Major Cardiovascular Events]. Praxis 2001;90:539–45.

    PubMed  CAS  Google Scholar 

  36. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash GB, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE, Simes J, Topol EJ. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418–31.

    Article  PubMed  CAS  Google Scholar 

  37. Berger K, Klose G, Szucs TD. Economic aspects of drug therapy exemplified by pravastation. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients. Med Klin 1997;92:363–9

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Social- and Preventive Medicine, University of Zurich, Gloriastrasse 18a, CH-8006, Zurich, Switzerland

    Thomas D. Szucs

  2. European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland

    Majbrit V. Holm & Matthias Schwenkglenks

  3. Emory University, Atlanta, GA, USA

    Zefeng Zhang & William S. Weintraub

  4. Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

    Michel Burnier

  5. Department of Cardiology, Kantonsspital Luzern, Luzern, Switzerland

    Paul Erne

Authors
  1. Thomas D. Szucs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Majbrit V. Holm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Schwenkglenks
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zefeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William S. Weintraub
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michel Burnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul Erne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas D. Szucs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szucs, T.D., Holm, M.V., Schwenkglenks, M. et al. Cost-Effectiveness of Eplerenone in Patients with Left Ventricular Dysfunction after Myocardial Infarction—An Analysis of the EPHESUS Study from a Swiss Perspective. Cardiovasc Drugs Ther 20, 193–204 (2006). https://doi.org/10.1007/s10557-006-8282-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-006-8282-y

Key words

Search

Navigation